Loading clinical trials...
Loading clinical trials...
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Conditions
Interventions
Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2
Start Date
June 1, 2011
Primary Completion Date
July 1, 2012
Completion Date
May 1, 2014
Last Updated
July 4, 2013
NCT07225114
NCT04618692
NCT00051545
NCT04518852
NCT06271109
NCT02094625
Lead Sponsor
Washington University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions